The etiology of benign prostatic hyperplasia (BPH) is still largely unresolved. Multiple partially overlapping and complementary systems (nerve, endocrine, immune, vascular) and local factors are likely to be involved (1), and therefore, several etiologic factors for BPH have been proposed to date (2). Primary interest has been focused on the steroid hormones, especially testosterone estrogen and their metabolites (3). Of the currently used BPH pharmacotherapeutic treatments, only the 5a-reductase inhibitors have been demonstrated to modify the underlying pathology scores and imaging studies (8). The best results have occurred in men with large prostates (> 40 grams), while all the 5a-Reductase Inhibitor’s (5ARI) effect takes approximately 3 to 6 months to occur (9). To our knowledge, of the currently used BPH pharmacotherapeutic interventions only the 5a-RI’s have been shown to modify the underlying pathology.